PMID- 30610472
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 10
IP  - 1
DP  - 2019 Feb
TI  - Efficacy Comparison of Preprandial and Postprandial Prandilin 25 Administration 
      in Patients with Newly Diagnosed Type 2 Diabetes Using a Continuous Glucose 
      Monitoring System.
PG  - 205-213
LID - 10.1007/s13300-018-0545-7 [doi]
AB  - INTRODUCTION: The aim of this study was to determine the clinical efficacy of 
      preprandial and postprandial Prandilin 25 (premixed insulin lispro 25) 
      administration in patients with newly diagnosed type 2 diabetes mellitus (T2DM) 
      using a continuous glucose monitoring (CGM) system. METHODS: This was a 
      single-center, self-controlled comparative clinical trial. Newly diagnosed T2DM 
      patients with hemoglobin A1c > 8.0% were hospitalized and received Prandilin 25 
      plus metformin treatment. Glycemic control was reached after a 7-to-8-day run-in 
      period. Patients underwent 2 days of treatment consisting of preprandial 
      Prandilin 25 on day 1 and postprandial Prandilin 25 on day 2 at the same dosage. 
      The primary outcome was the 24-h mean amplitude of glycemic excursion (24 hMAGE); 
      secondary outcomes were other daily glycemic variability parameters, including 
      24-h mean blood glucose (24hMBG), 24-h standard deviation of blood glucose 
      (24hSDBG), large amplitude of glycemic excursion (LAGE), incremental area under 
      the curve (AUC) values for different glucose levels, postprandial glucose 
      excursion, and incidence of hypoglycemia, which were assessed using a CGM system. 
      RESULTS: Eighty-five patients completed this study. There was no statistically 
      significant difference in 24hMAGE, 24hMBG, 24hSDBG, or LAGE between the 
      preprandial injection group and the postprandial injection group. Similarly, 
      there was no between-treatment difference in the AUC for a blood glucose level 
      below 3.9 mmol/L, in the AUC for a blood glucose level above 10.0 mmol/L, or in 
      the percentages of time that the blood glucose level was below 3.9 mmol/L or 
      above 10.0 mmol/L. Further analysis showed that the pre-meal glucose, peak 
      height, and time to peak after each meal, the relative areas under the CGM curve 
      at 1-4 h after each meal, as well as the incidence of hypoglycemia, were similar 
      for the preprandial and postprandial Prandilin 25 groups. CONCLUSION: In patients 
      with T2DM managed with premixed insulin lispro 25, postprandial injection (within 
      30 min of meal onset) may be an acceptable alternative to preprandial injection 
      when the regular preprandial insulin dose is omitted. TRIAL REGISTRATION: Chinese 
      Clinical Trial Register identifier: ChiCTR1800015828.
FAU - Luo, Yong
AU  - Luo Y
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Ni, Wen-Ji
AU  - Ni WJ
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Ding, B O
AU  - Ding BO
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Xu, Xiang-Hong
AU  - Xu XH
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Ye, Lei
AU  - Ye L
AD  - National Heart Research Institute Singapore, National Heart Centre, Singapore, 
      Singapore.
FAU - Ma, Jian-Hua
AU  - Ma JH
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China. majianhua@china.com.
FAU - Zhu, Jian
AU  - Zhu J
AUID- ORCID: 0000-0002-4629-9883
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China. drzhujian@hotmail.com.
LA  - eng
GR  - BL2014010/Scientific and Technological Development Program of Jiangsu Province/
GR  - JQX12006/The Nanjing Medical Science Fund for Distinguished Young Scholars/
PT  - Journal Article
DEP - 20190104
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC6349270
OTO - NOTNLM
OT  - Continuous glucose monitoring
OT  - Postprandial administration
OT  - Prandilin 25
OT  - T2DM
EDAT- 2019/01/06 06:00
MHDA- 2019/01/06 06:01
PMCR- 2019/01/04
CRDT- 2019/01/06 06:00
PHST- 2018/10/31 00:00 [received]
PHST- 2019/01/06 06:00 [pubmed]
PHST- 2019/01/06 06:01 [medline]
PHST- 2019/01/06 06:00 [entrez]
PHST- 2019/01/04 00:00 [pmc-release]
AID - 10.1007/s13300-018-0545-7 [pii]
AID - 545 [pii]
AID - 10.1007/s13300-018-0545-7 [doi]
PST - ppublish
SO  - Diabetes Ther. 2019 Feb;10(1):205-213. doi: 10.1007/s13300-018-0545-7. Epub 2019 
      Jan 4.